[A24-74] Fruquintinib (colorectal cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 28.11.2024
Project no.:
A24-74
Commission:
Commission awarded on 10.07.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Monotherapy for the treatment of adults with metastatic colorectal cancer who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents, and anti-epidermal growth factor receptor agents, and who have progressed on or are intolerant to treatment with either trifluridine/tipiracil or regorafenib
Hint of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2024-10-15.
https://doi.org/10.60584/A24-74_V1.1_en